Sign up to our newsletter

Polyclonal SARS-CoV-2 NP antibodies provide an excellent addition to the mix of antibodies to select for COVID-19 Antigen test development.

Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

 By watching this webinar, you will learn about:
- inflammation process and its clinical importance
- the clinical value of Interleukin-6 and other inflammation markers, as well as the benefits and limitations of these markers for diagnostics
- the role of Interleukin-6 in distinguishing the severity and prognosis of COVID-19

We have now developed 7 new MAb pairs to IL-6 that are suitable for high sensitivity IL-6 assay development.

Angiotensin converting enzyme 2 (ACE2) and SARS-CoV-2 Nucleoprotein fragment N47-A173 samples available

Call for nominations! We are delighted to let you know that we are sponsoring the EFLM-HyTest Cardiac Marker Award for remarkable scientific work in the field of cardiovascular diseases.

Early diagnosis of acute myocardial infarction (AMI) as a life-threatening disorder is important for immediate evidence-based therapy. The cardiac troponin I (cTnI) is a gold standard and diagnostic cornerstone in the clinical assessment of AMI. It offers accurate and rapid AMI rule outs.

Meet HyTest China team at the 18th China Association of Clinical Laboratory Practice Expo held at Chongqing International Expo Center, on 28-30 March.

New R&D samples available:
- Polyclonal anti-SARS-CoV-2 Nucleoprotein
- New anti-SARS-CoV-2 RBD clones

We are delighted to introduce our latest team member, Outi Vilamo and Netta Keinänen was appointed as the new Sales and Marketing Director from the beginning of January 2021

Our scientists presented an awarded poster at the virtual AACC 2020:
“Diverse Short-Term Natriuretic Response in Acute Decompensated Heart Failure Patients Undergoing Entresto™ Treatment"

Juhana Rauramo will become the new CEO of HyTest Group Oy with effect from January 1, 2021. Juhana has proven to be a very valuable person for HyTest and he has agreed to take on a more extensive role regarding the management of the company. Meanwhile, Maria Severina, the Founder and CEO of the company for the last 26 years will continue as a board member for HyTest Group Oy and she will be available as a consultant to the company.
Juhana has been the CCO of HyTest and a member of the management team since September 2019.

In this exceptional year we must make exceptional actions. Check our Season's Greetings video to you:

Connect with our representative during the AACC virtual expo, taking place December 14–17. Schedule a meeting at our booth through the virtual platform or contact us already now and agree a meeting.

Our new Sales Manager Outi Vilamo will be also waiting to meet you there.

We are pleased to let you know that we now have the first four anti-nucleoprotein antibodies available in their final forms.

Clinical Chemistry podcasts are highlighting selected articles in the journal. Now our scientists have been guests in the Clinical Chemistry podcasts related to their publications in the same journal.
Listen below the podcasts and learn more about our cardiac markers.

AACC’s Annual Scientific Meeting & Clinical Lab Expo, taking place December 14–17, will include many activities that you are used to experiencing in a live event: scientific sessions, poster presentations, an Expo showcase and networking opportunities.
If you or a representative of your company is planning to attend, we would welcome the opportunity to meet with you at our virtual booth.

Our first COVID-19 related monoclonal antibodies are now available

Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.

In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.